Literature DB >> 18316587

Macrophage inflammatory protein-1 delta: a novel osteoclast stimulating factor secreted by renal cell carcinoma bone metastasis.

Scott L Kominsky1, Samir M Abdelmagid, Michele Doucet, Kelly Brady, Kristy L Weber.   

Abstract

Approximately 30% of patients with renal cell carcinoma (RCC) develop bone metastasis, which is characterized by extensive osteolysis leading to severe bone pain and pathologic fracture. Although the mechanism of RCC-induced osteolysis is unknown, studies of bone metastasis have shown that tumor-induced changes in bone remodeling are likely mediated by alterations in the bone microenvironment. Here, we report the discovery of a novel osteoclast stimulatory factor secreted by RCC bone metastasis (RBM). Through microarray analysis, we found expression of the chemokine, macrophage inflammatory protein-1 delta (MIP-1 delta), to be increased in RBM versus patient-matched primary RCC tissues and confirmed this finding by quantitative reverse transcription-PCR (qRT-PCR) and ELISA (P < 0.05). Furthermore, MIP-1 delta expression in RBM tissues was significantly (P < 0.001) higher than in human bone marrow, suggesting a potential alteration of the bone microenvironment. The receptors for MIP-1 delta, CCR1 and CCR3, were expressed in both osteoclast precursors and mature, bone-resorbing osteoclasts as shown by qRT-PCR and Western analysis. In functional studies, MIP-1 delta stimulated chemotaxis of two osteoclast precursor cell types: murine bone marrow mononuclear cells (BM-MNC) and RAW 264.7 cells. Furthermore, MIP-1 delta treatment of murine calvaria caused increased bone resorption as determined by measurement of released calcium. Correspondingly, MIP-1 delta significantly enhanced osteoclast formation and activity in response to RANKL in both BM-MNC and RAW 264.7 cells. Taken together, these data suggest that MIP-1 delta expression is increased in RBM relative to RCC and bone marrow, and may promote RBM-induced osteolysis by stimulating the recruitment and differentiation of osteoclast precursors into mature osteoclasts.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18316587     DOI: 10.1158/0008-5472.CAN-07-6122

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  18 in total

1.  Mutation in Osteoactivin Promotes Receptor Activator of NFκB Ligand (RANKL)-mediated Osteoclast Differentiation and Survival but Inhibits Osteoclast Function.

Authors:  Samir M Abdelmagid; Gregory R Sondag; Fouad M Moussa; Joyce Y Belcher; Bing Yu; Hilary Stinnett; Kimberly Novak; Thomas Mbimba; Matthew Khol; Kurt D Hankenson; Christopher Malcuit; Fayez F Safadi
Journal:  J Biol Chem       Date:  2015-04-02       Impact factor: 5.157

2.  Blood-Based Biomarkers in High Grade Gliomas: a Systematic Review.

Authors:  Daniela Pierscianek; Yahya Ahmadipour; Marvin Darkwah Oppong; Laurèl Rauschenbach; Sied Kebir; Martin Glas; Ulrich Sure; Ramazan Jabbarli
Journal:  Mol Neurobiol       Date:  2019-02-04       Impact factor: 5.590

Review 3.  Molecular genetic studies of gene identification for osteoporosis: the 2009 update.

Authors:  Xiang-Hong Xu; Shan-Shan Dong; Yan Guo; Tie-Lin Yang; Shu-Feng Lei; Christopher J Papasian; Ming Zhao; Hong-Wen Deng
Journal:  Endocr Rev       Date:  2010-03-31       Impact factor: 19.871

4.  Deficiency of chemokine receptor CCR1 causes osteopenia due to impaired functions of osteoclasts and osteoblasts.

Authors:  Akiyoshi Hoshino; Tadahiro Iimura; Satoshi Ueha; Sanshiro Hanada; Yutaka Maruoka; Mitsuori Mayahara; Keiko Suzuki; Toshio Imai; Masako Ito; Yoshinobu Manome; Masato Yasuhara; Takaaki Kirino; Akira Yamaguchi; Kouji Matsushima; Kenji Yamamoto
Journal:  J Biol Chem       Date:  2010-06-22       Impact factor: 5.157

5.  Inactivation of chemokine (C-C motif) receptor 1 (CCR1) suppresses colon cancer liver metastasis by blocking accumulation of immature myeloid cells in a mouse model.

Authors:  Takanori Kitamura; Teruaki Fujishita; Pius Loetscher; Laszlo Revesz; Hiroki Hashida; Shinae Kizaka-Kondoh; Masahiro Aoki; Makoto M Taketo
Journal:  Proc Natl Acad Sci U S A       Date:  2010-06-29       Impact factor: 11.205

6.  Renal cell carcinoma bone metastases: clinical advances.

Authors:  Chakshu Sahi; Jennifer J Knox; Mark Clemons; Anthony M Joshua; Reuben Broom
Journal:  Ther Adv Med Oncol       Date:  2010-03       Impact factor: 8.168

7.  The functions and prognostic values of chemokine and chemokine receptors in gastric cancer.

Authors:  Chenglong He; Liping He; Qiaowei Lu; Jianjun Xiao; Wenjing Dong
Journal:  Am J Cancer Res       Date:  2022-07-15       Impact factor: 5.942

8.  Adsorbed fibrinogen enhances production of bone- and angiogenic-related factors by monocytes/macrophages.

Authors:  Joana Maciel; Marta I Oliveira; Erica Colton; Amy K McNally; Carla Oliveira; James M Anderson; Mário A Barbosa
Journal:  Tissue Eng Part A       Date:  2013-11-14       Impact factor: 3.845

9.  Does the onset of bone metastasis in sunitinib-treated renal cell carcinoma patients impact the overall survival?

Authors:  P Ivanyi; J Koenig; A Trummer; J F Busch; C Seidel; C W Reuter; A Ganser; V Grünwald
Journal:  World J Urol       Date:  2015-11-19       Impact factor: 4.226

10.  MIP-1δ activates NFATc1 and enhances osteoclastogenesis: involvement of both PLCγ2 and NFκB signaling.

Authors:  Kristy L Weber; Michele Doucet; Adam Shaner; Nigel Hsu; David Huang; Jenna Fogel; Scott L Kominsky
Journal:  PLoS One       Date:  2012-07-09       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.